- Home
- FOXX vs TGTX Comparison
FOXX vs TGTX Comparison
Compare FOXX & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- TGTX
- Stock Information
- Founded
- FOXX 2017
- TGTX 1993
- Country
- FOXX United States
- TGTX United States
- Employees
- FOXX N/A
- TGTX N/A
- Industry
- FOXX
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FOXX
- TGTX Health Care
- Exchange
- FOXX Nasdaq
- TGTX Nasdaq
- Market Cap
- FOXX 32.2M
- TGTX 4.2B
- IPO Year
- FOXX N/A
- TGTX 1995
- Fundamental
- Price
- FOXX $5.05
- TGTX $32.04
- Analyst Decision
- FOXX
- TGTX Strong Buy
- Analyst Count
- FOXX 0
- TGTX 5
- Target Price
- FOXX N/A
- TGTX $45.00
- AVG Volume (30 Days)
- FOXX 27.8K
- TGTX 2.1M
- Earning Date
- FOXX 10-24-2025
- TGTX 11-03-2025
- Dividend Yield
- FOXX N/A
- TGTX N/A
- EPS Growth
- FOXX N/A
- TGTX N/A
- EPS
- FOXX N/A
- TGTX 0.36
- Revenue
- FOXX $53,866,257.00
- TGTX $454,069,000.00
- Revenue This Year
- FOXX N/A
- TGTX $82.58
- Revenue Next Year
- FOXX N/A
- TGTX $44.99
- P/E Ratio
- FOXX N/A
- TGTX $88.81
- Revenue Growth
- FOXX 3899.98
- TGTX 30.96
- 52 Week Low
- FOXX $2.45
- TGTX $21.16
- 52 Week High
- FOXX $12.80
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- FOXX 41.09
- TGTX 56.50
- Support Level
- FOXX $4.75
- TGTX $31.29
- Resistance Level
- FOXX $5.86
- TGTX $32.56
- Average True Range (ATR)
- FOXX 0.62
- TGTX 1.15
- MACD
- FOXX -0.07
- TGTX 0.32
- Stochastic Oscillator
- FOXX 26.60
- TGTX 73.48
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.